A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam

被引：0
|
作者：
Schon, Miguel [1 ]
Domingues, Sara [2 ]
Moreno, Teresa [3 ]
Santos, Miguel Oliveira [1 ,4 ]
机构：
[1] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Neurosci & Mental Hlth, Ave Prof Egas Moniz, P-1649028 Lisbon, Portugal
[2] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Dept Phys Med & Rehabil, Lisbon, Portugal
[3] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Pediat Neurol Unit, Lisbon, Portugal
[4] Univ Lisbon, Inst Physiol, Fac Med, Inst Med Mol JLA, Lisbon, Portugal
来源：
NEUROLOGICAL SCIENCES | 2023年 / 44卷 / 04期
关键词：
D O I：
10.1007/s10072-022-06539-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：1449 / 1450
页数：2
相关论文
共 50 条
  • [31] RAINBOWFISH: A study of risdiplam in infants with presymptomatic spinal muscular atrophy (SMA)
    Servais, L.
    Al-Muhaizea, M.
    Farrar, M.
    Nelson, L.
    Prufer, A.
    Finkel, R.
    Wang, Y.
    Zanoteli, E.
    El-Khairi, M.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Scalco, R.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S48 - S48
  • [32] RAINBOWFISH: A Study of Risdiplam in Newborns with Presymptomatic Spinal Muscular Atrophy (SMA)
    Finkel, Richard S.
    Al-Muhaizea, Mohammad
    Farrar, Michelle A.
    Nelson, Leslie
    Prufer, Alexandra
    Servais, Laurent
    Wang, Yi
    Zanoteli, Edmar
    Palfreeman, Laura
    El-Khairi, Muna
    Gorni, Ksenija
    Kletzl, Heidemarie
    Gerber, Marianne
    Scalco, Renata S.
    Bertini, Enrico
    NEUROLOGY, 2021, 96 (15)
  • [33] FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy
    Deconinck, N.
    Baranello, G.
    Boespflug-Tanguy, O.
    Day, J.
    Klein, A.
    Masson, R.
    Mazurkiewicz-Beldzinska, M.
    Mercuri, E.
    Rose, K.
    Servais, L.
    Vlodavets, D.
    Xiong, H.
    Zanoteli, E.
    El-Khairi, M.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Dodman, A.
    Gaki, E.
    Darras, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 279 - 279
  • [34] Large deletions within the spinal muscular atrophy gene region in a patient with spinal muscular atrophy type 3
    Wei, Wei
    Chen, Chunyue
    Liu, Wenting
    Du, Zhenfang
    Chen, Xiaoling
    Zhang, Xianning
    NEURAL REGENERATION RESEARCH, 2011, 6 (23) : 1810 - 1813
  • [35] Large deletions within the spinal muscular atrophy gene region in a patient with spinal muscular atrophy type 3
    Wei Wei1
    Neural Regeneration Research, 2011, 6 (23) : 1810 - 1813
  • [36] Real-world evidence: Risdiplam in a patient with spinal muscular atrophy type I with a novel splicing mutation and one SMN2 copy
    Ma, Kai
    Zhang, Kaihui
    Chen, Defang
    Wang, Chuan
    Abdalla, Mohnad
    Zhang, Haozheng
    Tian, Rujin
    Liu, Yang
    Song, Li
    Zhang, Xinyi
    Liu, Fangfang
    Liu, Guohua
    Wang, Dong
    HUMAN MOLECULAR GENETICS, 2024, 33 (13) : 1120 - 1130
  • [37] Is treatment with oral risdiplam effective and well-tolerated for infants with spinal muscular atrophy type 1?
    Gaffar, Sheema
    Cayabyab, Rowena
    Ramanathan, Rangasamy
    JOURNAL OF PERINATOLOGY, 2022, 42 (05) : 689 - 691
  • [38] Is treatment with oral risdiplam effective and well-tolerated for infants with spinal muscular atrophy type 1?
    Sheema Gaffar
    Rowena Cayabyab
    Rangasamy Ramanathan
    Journal of Perinatology, 2022, 42 : 689 - 691
  • [39] Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study
    Claudia A. Chiriboga
    Claudio Bruno
    Tina Duong
    Dirk Fischer
    Eugenio Mercuri
    Janbernd Kirschner
    Anna Kostera-Pruszczyk
    Birgit Jaber
    Ksenija Gorni
    Heidemarie Kletzl
    Imogen Carruthers
    Carmen Martin
    Francis Warren
    Renata S. Scalco
    Kathryn R. Wagner
    Francesco Muntoni
    Neurology and Therapy, 2023, 12 : 543 - 557
  • [40] RAINBOWFISH: Preliminary efficacy and safety data in risdiplam-treated infants with presymptomatic spinal muscular atrophy (SMA)
    Finkel, R.
    Farrar, M.
    Vlodavets, D.
    Zanoteli, E.
    Al-Muhaizea, M.
    Nelson, L.
    Prufer, A.
    Servais, L.
    Wang, Y.
    Fisher, C.
    Gerber, M.
    Gorni, K.
    Kletzl, H.
    Palfreeman, L.
    Scalco, R.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2022, 32 : S85 - S86
12345